Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.
Zacks.com on MSN8h
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in EuropeBiogen Inc.’s BIIB Japan-based partner, Eisai announced that the European Medicines Agency’s (EMA) Committee for Medicinal ...
The company’s shares closed yesterday at $164.89. According to TipRanks, Nadeau is a 4-star analyst with an average return of 6.5% and a 46.88% success rate. Nadeau covers the Healthcare sector, ...
22h
Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced a positive opinion has been received from the Committee for Medicinal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback